Related Experiment Videos
Lung surfactant enhancement in utero
G C Di Renzo1, M M Anceschi, E V Cosmi
1Institute of Gynecology and Obstetrics, University of Perugia, Italy.
Summary
Glucocorticoids (GC) reduce neonatal respiratory distress syndrome (RDS) but have side effects. Ambroxol shows promise, and inositol may mitigate GC adverse effects, improving fetal lung maturity.
Area of Science:
- Neonatal Medicine
- Pharmacology
- Obstetrics
Background:
- Neonatal respiratory distress syndrome (RDS) is a significant concern in preterm infants.
- Antenatal administration of glucocorticoids (GC) is a primary strategy to accelerate fetal lung maturity and prevent RDS.
Purpose of the Study:
- To review strategies for preventing neonatal RDS, focusing on antenatal drug administration.
- To evaluate the efficacy and safety of various drugs, including glucocorticoids, ambroxol, aminophylline, and inositol, in promoting fetal lung maturity.
Main Methods:
- Review of existing literature on antenatal drug administration for RDS prevention.
- Experimental studies evaluating aminophylline's effects on fetal lung maturation.
- Evaluation of the combined effects of glucocorticoids and inositol on fetal lung mechanisms in pregnant rabbits.
Main Results:
- Glucocorticoids (GC) are effective in reducing RDS incidence in neonates born between 28-32 weeks gestation.
- Ambroxol significantly reduces RDS compared to placebo with no major adverse effects.
- Aminophylline demonstrated minor benefits for fetal lung maturation, while inositol mitigated adverse effects of GC on fetal lung development in rabbits.
Conclusions:
- Ambroxol is a potential alternative to GC for RDS prevention due to its efficacy and safety profile.
- Inositol may enhance the safety of GC therapy by reducing their adverse effects on fetal lung development.
- Comprehensive strategies including risk identification, guideline development, fetal lung maturity assessment, intrapartum monitoring, and prevention of birth asphyxia are crucial for minimizing neonatal RDS.